Overview

* Adicet Bio ( ACET ) Q3 net loss narrows to $26.9 mln from $30.5 mln, with reduced operating expenses

* Positive preliminary data from Phase 1 trial of ADI-001 in lupus nephritis and SLE

* Company raises $74.8 mln in direct offering, extending cash runway into 2H 2027

Outlook

* Company plans FDA meeting in 1Q/2026 for pivotal ADI-001 trial design

* Adicet to submit regulatory filing for ADI-212 in 1Q/2026

* Company extends cash runway into 2H/2027 following capital raise

Result Drivers

* R&D EXPENSES - R&D expenses fell to $22.9 mln from $26.3 mln due to lower payroll, lab supplies, CDMO and R&D consultation costs

* CAPITAL RAISE - Co raised $74.8 mln in direct offering, extending cash runway into 2H/2027

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$26.86

Income mln

Q3 Basic -$0.29

EPS

Q3 $27.95

Operatin mln

g

Expenses

Q3 -$27.95

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Adicet Bio Inc ( ACET ) is $6.50, about 89.4% above its November 4 closing price of $0.69

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)